Skip to main content

Day: November 3, 2023

Tenable to Participate in Upcoming Investor Events

COLUMBIA, Md., Nov. 03, 2023 (GLOBE NEWSWIRE) — Tenable®, the Exposure Management company, today announced its chief financial officer, Steve Vintz, is scheduled to attend the Needham Infrastructure, Data Analytics, & Cloud Communications Virtual Conference, D.A. Davidson Technology Summit and Barclays Global Technology Conference. Tenable chairman and chief executive officer, Amit Yoran, will join Vintz to attend the Wells Fargo TMT Summit. Yoran will participate in a fireside chat at the Stephens Annual Investment Conference. Details for each event are as follows: 5th Annual Needham Infrastructure, Data Analytics, & Cloud Communications Virtual ConferenceNovember 15, 2023 2023 D.A. Davidson Technology SummitNovember 16, 2023 Stephens Annual Investment ConferenceNovember 17, 2023 7th Annual Wells Fargo TMT SummitNovember...

Continue reading

Davie Completes Purchase Of The Assets Of Helsinki Shipyard

LEVIS, Québec, Nov. 03, 2023 (GLOBE NEWSWIRE) — Davie today announced it has finalized the acquisition of the assets of Finland’s Helsinki Shipyard Oy (HSO). The historic transaction combines the skills, experience and capabilities of two leaders in Arctic shipbuilding and other high-value products. While the Canadian and Finnish shipyard will be separate legal and operating entities, the business headquarters will remain in Québec. The transaction will create opportunities for employees, encourage collaboration, facilitate the transfer of know-how, provide access to resources, and stimulate export potential. While the details of the business purchase agreement are confidential, the transaction was made possible by a combination of Davie’s own funds and by €77 million ($110 million) of financing from the Québec government consisting...

Continue reading

Davie Completes Purchase of the Assets of Helsinki Shipyard

Helsinki ShipyardHelsinki ShipyardLEVIS, Québec, Nov. 03, 2023 (GLOBE NEWSWIRE) — Davie today announced it has finalized the acquisition of the assets of Finland’s Helsinki Shipyard Oy (HSO). The historic transaction combines the skills, experience and capabilities of two leaders in Arctic shipbuilding and other high-value products. While the Canadian and Finnish shipyard will be separate legal and operating entities, the business headquarters will remain in Québec. The transaction will create opportunities for employees, encourage collaboration, facilitate the transfer of know-how, provide access to resources, and stimulate export potential. While the details of the business purchase agreement are confidential, the transaction was made possible by a combination of Davie’s own funds and by €77 million ($110 million) of...

Continue reading

Chamonix Casino Hotel Announces Reservations Are Now Open

The Casino and Hotel will officially open on December 26, 2023 CRIPPLE CREEK, Colo., Nov. 03, 2023 (GLOBE NEWSWIRE) — Chamonix Casino Hotel announced today that hotel reservations for Colorado’s newest casino destination are now open. The 300-room hotel will feature the first luxury guest rooms in the Cripple Creek market, skillfully blending the comfort and charm of Colorado with European elegance. Both the casino and hotel are scheduled to open to the public on December 26, 2023. Located adjacent to our existing Bronco Billy’s Casino, Chamonix will feature a spacious, new, stylish and exciting casino gaming area; a fine-dining restaurant operated by Barry Dakake, a celebrated chef known for leading several steakhouses in Las Vegas; a rooftop pool and high-end spa; entertainment and meeting space, including a 5,100-square-foot...

Continue reading

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestatThe Company extended its expected cash runway into 2026Clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome remain on track; Takeda anticipates regulatory filings in its fiscal year 2024Ovid recently hosted an R&D Day during which the Company announced indication and formulation expansions associated with the OV329 and KCC2 direct activator programsOvid expects to achieve five clinical and regulatory milestones for its wholly owned pipeline in the next 15 monthsNEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

Continue reading

IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results

Reports record revenue of $16.5 million for the third quarter of 2023.GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022.WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. “I am pleased to announce that in the third quarter of 2023, we not only achieved record revenue...

Continue reading

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CISCompany initiated Phase 2 trial of TARA-002 in Lymphatic MalformationsCash, cash equivalents and investments of $74M as of September 30, 2023 expected to fund operations into Q2 of 2025NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update. “Progress continues across our TARA-002 clinical development programs, with patient dosing...

Continue reading

Applied Materials Announces Q4 and Fiscal 2023 Earnings Webcast

SANTA CLARA, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Applied Materials, Inc. will hold a webcast to discuss its fourth quarter and fiscal 2023 financial results on Thursday, Nov. 16, 2023 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast will be accessible via the Applied Materials website at: https://ir.appliedmaterials.com. A replay will be available on the same day beginning at 8:00 p.m. ET / 5:00 p.m. PT. About Applied MaterialsApplied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible a better future. Learn more at www.appliedmaterials.com. Contact:Ricky...

Continue reading

Plains All American Reports Third-Quarter 2023 Results & Raises 2023 Guidance

Announces Capital Allocation Updates & Permian Bolt-On Acquisitions HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported third-quarter 2023 results and provided updated 2023 guidance as highlighted below. Plains also provided additional information regarding its multi-year capital allocation framework and announced two bolt-on acquisitions in the Permian Basin. Third-Quarter ResultsReported Net income attributable to PAA of $203 million and Net cash provided by operating activities of $85 million. Delivered strong results with Adjusted EBITDA attributable to PAA of $662 million.2023 Guidance UpdateRaising guidance for full-year 2023 Adjusted EBITDA attributable to PAA to $2.60 – $2.65 billion from $2.45 – $2.55 billion.Capital...

Continue reading

Auction result of Treasury Bonds – RIKB 28 1115 – RIKS 37 0115

Series  RIKB 28 1115 RIKS 37 0115Settlement Date  11/08/2023 11/08/2023Total Amount Allocated (MM)  5,100 2,394All Bids Awarded At (Price / Yield)  88.300 / 7.910 81.000 / 2.736Total Number of Bids Received  22 22Total Amount of All Bids Received (MM)  6,700 4,834Total Number of Successful Bids  18 13Number of Bids Allocated in Full  18 13Lowest Price / Highest Yield Allocated  88.300 / 7.910 81.000 / 2.736Highest Price / Lowest Yield Allocated  88.450 / 7.870 81.350 / 2.700Lowest Price / Highest Yield Allocated in Full  88.300 / 7.910 81.000 / 2.736Weighted Average of Successful Bids (Price/Yield)  88.374 / 7.890 81.154 / 2.720Best Bid (Price / Yield)  88.450 / 7.870 81.350 / 2.700Worst Bid (Price / Yield)  88.170 / 7.950 80.500 / 2.787Weighted Average of All Bids Received (Price / Yield)  88.341 / 7.900 80.959 / 2.740Percentage...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.